ArticleAging2024

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.

Shigui Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.